Intellia Therapeutics Announces Initiation of Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (Hae)
intellia therapeutics宣佈啓動Haelo第3階段研究，研究Ntla-2002，一種用於遺傳性血管性水腫（Hae）的體內CRISPR基因編輯治療的實驗性藥物。